Lactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment

Basit Öğe Kaydı
dc.authoridEker, Furkan/0009-0002-5260-6111
dc.authoridBolat, Ecem/0009-0001-7086-3317
dc.authoridKARAV, SERCAN/0000-0003-4056-1673
dc.contributor.authorEker, Furkan
dc.contributor.authorBolat, Ecem
dc.contributor.authorPekdemir, Burcu
dc.contributor.authorDuman, Hatice
dc.contributor.authorKarav, Sercan
dc.date.accessioned2025-01-27T21:19:47Z
dc.date.available2025-01-27T21:19:47Z
dc.date.issued2023
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractParkinson's disease (PD) is the second-most common neurodegenerative disease and is largely caused by the death of dopaminergic (DA) cells. Dopamine loss occurs in the substantia nigra pars compacta and leads to dysfunctions in motor functions. Death of DA cells can occur with oxidative stress and dysfunction of glial cells caused by Parkinson-related gene mutations. Lactoferrin (Lf) is a multifunctional glycoprotein that is usually known for its presence in milk, but recent research shows that Lf is also found in the brain regions. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a known mitochondrial toxin that disturbs the mitochondrial electron transport chain (ETC) system and increases the rate of reactive oxygen species. Lf's high affinity for metals decreases the required iron for the Fenton reaction, reduces the oxidative damage to DA cells caused by MPTP, and increases their surveillance rate. Several studies also investigated Lf's effect on neurons that are treated with MPTP. The results pointed out that Lf's protective effect can also be observed without the presence of oxidative stress; thus, several potential mechanisms are currently being researched, starting with a potential HSPG-Lf interaction in the cellular membrane of DA cells. The presence of Lf activity in the brain region also showed that lactoferrin initiates receptor-mediated transcytosis in the blood-brain barrier (BBB) with the existence of lactoferrin receptors in the endothelial cells. The existence of Lf receptors both in endothelial cells and DA cells created the idea of using Lf as a secondary molecule in the transport of therapeutic agents across the BBB, especially in nanoparticle development.
dc.description.sponsorshipUluova Suet Ticaret A.S. (Uluova Milk Trading Co.); Tuebitak; [118z146]
dc.description.sponsorshipUluova Suet Ticaret A.S. (Uluova Milk Trading Co.) and Tuebitak (#118z146) have funded this study. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
dc.identifier.doi10.3389/fnagi.2023.1204149
dc.identifier.issn1663-4365
dc.identifier.pmid37731953
dc.identifier.scopus2-s2.0-85171594777
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3389/fnagi.2023.1204149
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28735
dc.identifier.volume15
dc.identifier.wosWOS:001069518300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers in Aging Neuroscience
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectlactoferrin
dc.subjectParkinson's disease
dc.subjectneuroprotection
dc.subjectheparan sulfate proteoglycans
dc.subjectdopaminergic cells
dc.subjectMPTP
dc.titleLactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu